After multiple studies, MannKind finally wins an FDA OK for inhaled insulin Afrezza

John Carroll

Three years and hundreds of millions of dollars was handed its second FDA rejection on , the third time proved the charm for the . The FDA on Friday handed out its blessing for MannKind to start marketing the drug, which will now set out to see if it can succeed with an inhaled Pfizer's Exubera failed so spectacularly at the task.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS